ScholarIQanswers from OpenAlex & ORCID
Franck Morschhauser
ResearcherPublications, citations & collaboration network
Franck Morschhauser is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Franck Morschhauser have?
ScholarIQindexed works
Franck Morschhauser has 921 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Franck Morschhauser have?
ScholarIQcitation count
Franck Morschhauser has 34,883 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Franck Morschhauser?
ScholarIQh-index
Franck Morschhauser has an h-index of 94 in OpenAlex.
What is the i10-index of Franck Morschhauser?
ScholarIQi10-index
Franck Morschhauser has an i10-index of 384 in OpenAlex.
What is the ORCID of Franck Morschhauser?
ScholarIQorcid
The ORCID for Franck Morschhauser is on the source record.
What is the OpenAlex record for Franck Morschhauser?
ScholarIQopenalex
The OpenAlex for Franck Morschhauser is on the source record.
What are the most-cited papers on Franck Morschhauser?
ScholarIQmost cited works
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, R. Neuhaus, H. Lehmkuhl, Heinz A. Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphaël, Hanno Riess, Sylvain Choquet
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
Charles Herbaux, Jordan Gauthier, Pauline Brice, Élodie Drumez, Loïc Ysebaert, Hélène Doyen, Luc Mathieu Fornecker, Krimo Bouabdallah, Guillaume Manson, Hervé Ghesquières, Reza Tabrizi, Éric Hermet, Julien Lazarovici, Anne Thiebaut‐Bertrand, Adrien Chauchet, Hélène Demarquette, Eileen M. Boyle, Roch Houot, Ibrahim Yakoub‐Agha, Franck Morschhauser